Arcellx provides fourth quarter and year-end 2023 financial results and business highlights

-- expanded strategic partnership with kite -- -- presented continued robust long-term responses from phase 1 expansion trial of anito-cel (formerly cart-ddbcma) in patients with relapsed or refractory multiple myeloma -- -- ended the quarter with $729.2m, extending cash runway into 2027 -- redwood city, calif. , feb. 28, 2024 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended december 31, 2023.
ACLX Ratings Summary
ACLX Quant Ranking